glp-1 and glp-2 drugs medication its types Primer: The Skinny on GLP-1s

This limits access for many patients seeking GLP-1 drugs for weight management

East Asia: In East Asia, China and Japan are experiencing strong demand for GLP-1 receptor agonists, driven by an increasing prevalence of type 2 diabetes and expanding access to diabetes treatments

Our results are generally consistent in direction and magnitude with the existing clinical research, including trials showing reduced heavy alcohol consumption among those with obesity,14 reduced drinking in an experimental bar setting,12 and pharmacoepidemiological analyses showing that GLP-1 receptor agonists are associated with lower incidence and recurrence of alcohol use disorder,2 reduced need for tobacco use related care,5 lower incidence and relapse of cannabis use disorder,4 and reduced risk of opioid overdose in patients with opioid use disorders.8 Our results show that among people with a pre-existing SUD, GLP-1 receptor agonist use was associated with a reduced risk of several adverse clinical outcomes (SUD related emergency department visits, hospital admission, and mortality, drug overdose, and suicidal attempt or ideation)

Between 2021 and 2026, GLP-1 prescriptions for weight loss quadrupled from just under 3% to nearly 13%, according to Epic Research

That's a lot of people at an increased risk of health complications